Hepatomegaly results from diverse inflammatory, infiltrative, and congestive disorders. Massive hepatomegaly may arise from amyloidosis and can rarely be a sole presenting manifestation of this systemic disorder.
KastritisEDimopoulosMA. Recent advances in the management of AL amyloidosis. Br J Haematol2016; 172: 170–186.
2.
MauermannMLClarkeJOLitchyWJ, et al.Peripheral nervous, hepatic, and gastrointestinal endpoints for AL amyloidosis clinical trials: report from the amyloidosis forum multi-organ system working group. Adv Ther2023; 40: 4695–4710.
3.
EbertECNagarM. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol2008; 103: 776–787.
4.
DahiyaDSKichlooASinghJ, et al.Gastrointestinal amyloidosis: a focused review. World J Gastrointest Endosc2021; 13: 1–12.
5.
GodskesenLAbildgaardNKjeldsenJ, et al.A rare cause of severe hepatomegaly with an improving outcome. BMJ Case Rep2014; 2014: bcr2013203360.
6.
PalladiniGSchönlandSMerliniG, et al.The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J2023; 13: 19.
7.
SidanaSMilaniPBinderM, et al.A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer J2020; 10: 41.
8.
GertzMADispenzieriA. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA2020; 324: 79–89.
9.
AzzamMKawtharanyHNazzalJ, et al.Diagnostic test accuracy of fat pad sampling and bone marrow biopsies in the diagnosis of AL amyloidosis: a systematic review and meta-analysis. Blood2024; 144: 6896.
10.
LockeMNietoM. AL Amyloidosis: current treatment and outcomes. Adv Hematol2025; 2025: 7280805.
